Arcutis Biotherapeutics (ARQT) Q3 2026 earnings review
Arcutis drug sales rise, but marketing bills cut quarterly profit
Arcutis Biotherapeutics, the maker of Zoryve steroid-free prescription skin creams and foams, grew sales while heavy marketing spend cut profit. Product revenue rose 45% from a year ago to $144 million, and chief executive Frank Watanabe raised the full-year outlook again. However, operating profit fell from $16 million last quarter to $9 million because celebrity advertising and new sales reps pushed overhead costs up.
| Product revenue | $143.9M +45% from a year ago, +11% from last quarter |
|---|---|
| Zoryve foam 0.3% revenue | $75.1M 52% of total sales, +51% from a year ago |
| Operating profit | $9.4M down from $16.4M last quarter on ad and sales hiring costs |
| Full-year sales outlook | Raised $7.5M to $535–545M (middle of the range: 45% growth) |
⚖️ Verdict: 🔴 Bearish
The story got worse because quarter-to-quarter sales growth slowed by half just as marketing bills jumped. Last quarter's 23% quarterly revenue gain dropped to 11%, landing inside the slower pace implied by the prior outlook and showing that the earlier plan was realistic rather than cautious. On the bright side, Zoryve foam crossed half of total revenue and operating cash flow reached $19 million.
The question now is whether the new primary care sales force and celebrity ad campaign will lift prescription growth in 2027 or just leave the company with higher fixed costs. Optimists see necessary upfront spending before new prescriptions show up, while skeptics note that an earlier primary care partnership failed to gain traction. Fourth-quarter prescription volumes and selling costs as a share of revenue will tell.
🐂 Bull Case
Foam Carries Over Half of All Drug Sales
Arcutis sells Zoryve, a steroid-free prescription skin medicine made in four versions across creams and a foam. "ZORYVE continues to lead the branded non-steroidal topical segment driven by its efficacy and tolerability across multiple inflammatory skin conditions and patient populations," chief executive Frank Watanabe said.
Every version grew in the third quarter, led by the foam for scalp and body conditions. That foam now brings in more than half of the drugmaker's revenue by our math, and the newest mild cream for young children also gained ground.
- Zoryve foam 0.3%: $75.1 million, up 50.8% from a year ago and 11.4% from last quarter by our math
- Zoryve cream 0.3% (psoriasis): $37.8 million, up 23.9% from a year ago by our math
- Zoryve cream 0.15% (eczema): $27.3 million, up 44.4% from a year ago by our math
- Zoryve cream 0.05% (pediatric eczema): $3.7 million, up 27.6% from last quarter by our math
This mix shift matters because the foam is growing more than twice as fast from a year ago as the original psoriasis cream. As long as the foam and newer eczema creams take a larger share of sales, they support overall growth even as the older psoriasis cream matures.
What to watch: fourth-quarter revenue by product in the annual filing. Continued double-digit quarterly growth in the foam and pediatric creams would show the newer uses are still expanding the patient base.
New Trials and Cash Generation Fund Expansion
The dermatology group wants to use cash from current Zoryve sales to pay for clinical trials in new skin conditions without selling more shares. This quarter, the business generated $18.9 million in cash from operations, up from $12.6 million in the second quarter, lifting cash and marketable securities to $259.8 million.
Arcutis used that money to start a late-stage Phase 3 trial of its 0.3% cream for moderate-to-severe eczema and to prepare a mid-stage trial of its foam for skin rashes caused by cancer drugs. Research and development costs rose 14.4% from a year ago to $22.4 million, but dropped as a share of sales from 19.8% to 15.6% by our math.
What to watch: Phase 2 results and the advancement decision for Zoryve foam in vitiligo, a condition that causes loss of skin color, due before year-end. A decision to move into Phase 3 would give the foam a fourth major skin indication.
🐻 Bear Case
Sales and Marketing Costs Cut Operating Margin in Half
"Yet another strong quarter of performance reflects the consistent execution of our corporate strategy and further strengthens our financial position," chief executive Frank Watanabe said. Despite adding $14.1 million in new revenue from last quarter, operating profit fell from $16.4 million in the second quarter to $9.4 million in the third.
Selling and overhead costs drove the drop, rising 59.6% from a year ago and 21.3% from last quarter to $99.6 million. Arcutis spent heavily "primarily in support of the Skin to Believe In celebrity awareness campaign" with gymnast Simone Biles, and paid for new staff "resulting from the dermatology sales force expansion and launch of the primary care provider and pediatric sales team". The company also named a new permanent commercial chief, Rob Lisicki, effective November 4.
Those bills took 69.2% of revenue by our math, up 6.3 percentage points from a year ago, which cut operating margin from 12.7% last quarter to 6.6%. Spending ahead of revenue is a risk because the previous primary care partnership with Kowa failed to generate enough prescriptions and was ended in January.
What to watch: selling and overhead expenses as a share of sales in the fourth quarter, when the new primary care reps have been in the field for a full period. If costs stay near 69% of revenue while growth slows, the commercial expansion is not paying for itself.
Quarter-to-Quarter Sales Growth Slowed by Half
Last quarter, the full-year outlook pointed to second-half sales growth slowing down from the second quarter's 23.2% quarterly jump. Bulls thought that plan was just cautious because newly hired dermatology sales reps entered the field in May.
Instead, third-quarter product sales grew 10.8% from the second quarter to $143.9 million, landing inside the 8% to 11% quarterly pace implied by the prior outlook. Arcutis raised its full-year target by $7.5 million at the middle of the range to $535–545 million, a much smaller increase than last quarter's $45 million boost.
By our math, the new full-year target leaves $160.8 million for the fourth quarter at the middle of the range. That equals 11.7% growth from the third quarter and 26.1% growth from a year ago, down from 45.1% year-over-year growth this quarter because last year's fourth quarter was much larger.
What to watch: fourth-quarter net product revenue against the $155.8–165.8 million range implied by the full-year outlook. A result near the middle of that range would confirm that quarterly growth has settlednear 11% despite the expanded sales teams.
Prescription Counts Stay Dark as Discount Gains Fade
Net drug sales depend on two numbers: how many prescriptions doctors write, and the gross-to-net (GTN) rate, which is the share of the list price deducted for insurance rebates and patient discounts. Earlier this year, management said that discount rate would improve from the high 50s toward the low 50s, lifting revenue per prescription.
In the third-quarter release, the company said sales rose "predominantly due to increased unit demand, as well as modest improvements in gross-to-net (GTN) deductions". However, the release gave no weekly or quarterly prescription totals and no exact discount percentage. Without those figures in the release, investors cannot verify how much of the 10.8% quarterly growth came from new patients rather than smaller insurance rebates.
What to watch: the quarterly filing and conference call remarks for rolling four-week prescription numbers and the exact discount rate. Once the discount rate reaches the low 50s, all future revenue growth must come from prescription volume.
Risks this quarter didn't answer
Four standing concerns from prior quarters received no new information in the third-quarter press release.
- Generic patent challenge: Arcutis relies on one active drug molecule in the US and faces a paused patent challenge from generic maker Padagis; the quarterly filing's legal footnote will show if the case moved.
- Medicare coverage: Zoryve sits on a non-preferred tier for Medicare Part D patients until at least 2027; year-end contracting updates will show if coverage widens.
- Virtual health platform economics: management launched a telehealth channel last quarter without giving costs or prescription conversion rates; the call or filing may show whether it is driving volume.
- Ducentis promissory notes: the company owes $9.2 million in interest-free notes for an earlier drug acquisition that holders can demand starting this quarter; the filing's debt footnote will show if they were paid.
💲 Other KPIs
Stockpiles of raw materials and finished drugs doubled from $22.6 million at the end of 2025 and rose 103.7% from a year ago by our math, outpacing the 45.1% rise in sales. Inventory has climbed every quarter this year—from $37.4 million in Q1 to $38.9 million in Q2—tying up working capital ahead of pediatric and primary care launches.
Uncollected bills from drug wholesalers rose 48.8% from a year ago and 10.4% from last quarter by our math, moving in line with the 45.1% annual and 10.8% quarterly growth in product revenue. Receivables stood at $144.4 million in Q1 and $155.2 million in Q2, showing steady collection cycles as sales expand.
The diluted share count rose 3.0% from a year ago and 0.7% from last quarter by our math, driven by employee stock compensation rather than stock offerings. Rising share counts held diluted profit per share flat at $0.06 compared with a year ago, even though net income grew 18.8% to $8.8 million.
🔮 Guidance
Raised. The drugmaker lifted the middle of its full-year sales plan by $7.5 million to $540 million, or 45.1% growth from 2025 by our math. That leaves $160.8 million for Q4 at the middle of the range, meaning growth from a year ago slows to 26.1% against a tougher comparison. It is the third raise for 2026, following moves of +$25M, $0M, +$45M, and now +$7.5M.
❓ Key Questions
How many prescriptions were written in the third quarter?
The release did not include weekly or total prescription counts, nor the exact gross-to-net discount rate. Without them, investors cannot tell how much of the 10.8% quarterly sales increase came from patient volume versus smaller rebate deductions.
What return did the Simone Biles ad campaign deliver?
Selling and overhead expenses jumped by $17.5 million from last quarter to $99.6 million, cutting operating profit nearly in half. Management needs to show whether celebrity ads and the new primary care sales force are lifting prescriptions enough to cover their cost.
Why has inventory doubled since the end of 2025?
Inventory reached $45.7 million, up 102% in nine months and equal to more than three years of current cost of sales. Management should clarify how much of this build is for new pediatric launches versus safety stock.
Did Ducentis note holders demand their $9.2 million payment?
The interest-free promissory notes issued in April for the ARQ-234 milestone became callable by holders seven months after issuance, which falls in November. The release did not mention whether cash will leave the balance sheet this quarter to settle them.